A long-term study suggests GLP-1 agonists, especially semaglutide, may lower the risk of alcohol use disorder hospitalizations, highlighting the potential for novel treatments pending further ...

Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

A panelist discusses how glucagon-like peptide-1 receptor (GLP-1) agonists' cardioprotective effects likely stem from multiple physiological mechanisms, including reduced inflammation, improved ...

Asked why GLP-1 receptor agonists would influence such a diverse set of medical conditions, Al-Aly said a few different mechanisms might be at play. For one, it could be that addressing obesity by ...

The analysis found that obesity-related cancer occurred in 150 of 3,178 surgery patients (5.76 cases per 1,000 person-years) and in 148 of 3,178 patients taking GLP-1s (5.64 cases per 1,000 person ...

Among patients with morbid obesity, patients who were taking GLP-1s had a significant decrease in rates of periprosthetic joint infections (1% vs. 1.8%), medical complications (10.6% vs. 12.7% ...

Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Adv Ther. 2021;38 (6):2821-2839. doi:10.1007/s12325 ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight ...

Asif M, Asif A, Rahman UA, et al. Incidence of glaucoma in type 2 diabetes patients treated with GLP-1 receptor agonists: a systematic review and meta-analysis. 2025;8:e70059. doi:10.1002/edm2 ...

GLP-1 receptor agonists have been shown to reduce allergic airway inflammation and viral-induced airway inflammation,” Katherine N. Cahill, MD, medical director of clinical asthma research in ...